Selvita to present at Biotech Showcase 2017 in San Francisco

Krakow, Poland – 16 December 2016 – Selvita (WSE:SLV), a drug discovery company, announced today that its Chief Scientific Officer, Krzysztof Brzozka, will present at the upcoming Biotech Showcase Annual Conference, to be held in San Francisco on January 9 – 11, 2017.

The Biotech Showcase conference is one of the largest annual international healthcare conferences and will run parallel to the JP Morgan Healthcare Conference (San Francisco, January 9 -12, 2017). Investors and biopharmaceutical executives from around the world gather in San Francisco during the second week of January at a series of events which are widely viewed as setting the tone for the coming year.

Dr Brzozka’s presentation at the Biotech Showcase is scheduled as follows:

Date: Monday, January 9, 2017
Time: 3:30 PM
Venue: Room 7 (Ballroom Level) at Hilton San Francisco Union Square


Biotech ShowcaseTM (#BTS2017) is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Now in its 9th year, Biotech Showcase is expected to attract upwards of 2,000 attendees.



Selvita S.A. is a drug discovery company, developing breakthrough therapies in the area of oncology. The company’s most advanced R&D program is SEL24, a Phase I dual PIM/FLT3 kinase inhibitor.  Other projects include SEL120, a first-in-class small molecule inhibitor of CDK8 in preclinical studies, as well as several drug discovery platforms in immunooncology, immunometabolism and cancer metabolism as well as epigenetics performed independently or in collaboration with global pharma and biotech companies..

Selvita also offers a wide range of integrated drug discovery services, helping biotech and pharma partners discover and develop new drugs. The scope of services offer includes high quality services starting from chemistry (computational, medicinal, process chemistry, custom synthesis), through protein biochemistry up to complex in vitro preclinical studies in GLP (genotoxicity, ADME-Tox, PD, PK), as well as analytics with GMP and GLP certification.

The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Merck, H3 Biomedicine, Felicitex Therapeutics and Nodthera Therapeutics/Epidarex Capital.

The company was established in 2007 and currently employs over 365 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow, Poland, with international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK .